27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Individual statins were not significantly associated with risk of Parkinson's disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, gastric cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer. 3 key findings →
Design: cohort study Participants: 692 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings support the hypothesis that depression is a risk factor for dementia and suggest that recurrent depression is particularly pernicious. 3 key findings →
Design: longitudinal study Participants: 1,239 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High blood pressure increases the risks of stroke, dementia, and neurocognitive dysfunction. 2 key findings →
Participants: 124 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Classification of evidence This study provides Class II evidence that specific dual-task training improves dual-task performance during walking under complex S3 conditions in geriatric patients with mild to moderate dementia. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We conclude that there is evidence supporting the hypothesis that physical activity is likely to prevent the development of VaD, and should be highlighted as part of secondary prevention programmes in people at risk for cerebrovascular disease. 4 key findings →
Design: meta-analysis Participants: 1,378 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia. 3 key findings →
Design: longitudinal study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These results indicate that in both healthy subjects and patients with schizophrenia hippocampal volume is plastic in response to aerobic exercise. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
IER is as effective as CER with regard to weight loss, insulin sensitivity and other health biomarkers, and may be offered as an alternative equivalent to CER for weight loss and reducing disease risk. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Subjects were 404 persons in the Religious Orders Study, a cohort study of aging, who underwent annual clinical evaluations, including 19 neuropsychological tests from which 5 cognitive domain and global summary scores were derived, and brain autopsy at time-of-death (mean age-at-death 86). 4 key findings →
Design: cohort study Participants: 404 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The number of people with dementia from minority ethnic (ME) groups in western countries is projected to rise dramatically, and they may be less able to access dementia services. 1 key finding →
Design: systematic review Participants: 2,090 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The prediction of dementia in AD by SMI with subsequent amnestic MCI supports the model of a consecutive 3-stage clinical manifestation of AD from SMI via MCI to dementia. 2 key findings →
Design: cohort study Participants: 2,415 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
An overall rating of the quality of evidence was assigned by using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A mortality risk score derived from MDS data predicted six-month survival in advanced dementia with moderate accuracy. 1 key finding →
Design: cohort study Participants: 22,405 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In most of the decedents, the course of disability in the last year of life did not follow a predictable pattern based on the condition leading to death. 1 key finding →
Design: longitudinal study Participants: 65 Evidence: moderate
Full summary, score breakdown and related studies → Original source
To examine the relationship between smoking and Alzheimer's disease (AD) after controlling for study design, quality, secular trend, and tobacco industry affiliation of the authors, electronic databases were searched; 43 individual studies met the inclusion criteria. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
The findings support the clinical efficacy of CR in early-stage AD. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among the 158 participants who accurately recalled their Alzheimer disease risk assessment 6 weeks after risk disclosure, 75 (47.5%) believed their Alzheimer disease risk was more than 5% points different from the Alzheimer disease risk estimate they were given. 2 key findings →
Design: randomized controlled trial Participants: 158 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Low levels of vitamin D were associated with substantial cognitive decline in the elderly population studied over a 6-year period, which raises important new possibilities for treatment and prevention. 5 key findings →
Participants: 858 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
NPTs emerge as a useful, versatile and potentially cost-effective approach to improve outcomes and QoL in ADRD for both the PWD and CG. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. 1 key finding →
Participants: 515 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Follow-up case-control association study. 4 key findings →
Design: case-control study Participants: 1,829 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These results strengthen the clinical evidence that AD is accompanied by an inflammatory response, particularly higher peripheral concentrations of IL-6, TNF-α, IL-1β, TGF-β, IL-12 and IL-18 and higher CSF concentrations of TGF-β. 5 key findings →
Participants: 680 Evidence: low
Full summary, score breakdown and related studies → Original source
Median survival was much lower than in screened populations. 3 key findings →
Design: cohort study Participants: 22 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →